A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging

Satterlee, Andrew; Yuan, Hong; Huang, Leaf

doi:10.1016/j.jconrel.2015.08.048

Cited by 43 publications

(38 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…177 Lu is a good model isotope because its 6.6 day half-life provides the researcher a relatively long time to perform experiments before it decays, and the gamma component of its decay allows simple quantification of signal as well as live animal imaging using SPECT 1. Despite these advantages, 177 Lu has a fairly low beta energy (max = 0.5 Megaelectron-volts (MeV)) with an average path length in tissue of only 200-300 μm 21.…”

Section: Resultsmentioning

confidence: 99%

“…LPC encapsulation of CDDP was determined by nuclear magnetic resonance and X-ray photoelectron spectroscopy, and drug loading of cisplatin (cis-diamminedichloridoplatinum(II), or CDDP) was determined by Inductively Coupled Plasma Mass Spectroscopy (ICP-MS). 177 Lu/ 90 Y-LCP fabrication was slightly modified from what is described in a previous publication 1. Two reverse microemulsions were prepared in round-bottom flasks.…”

Section: Methodsmentioning

confidence: 99%

“…We have previously published on the antitumor efficacy of our 177 Lutetium ( 177 Lu)-loaded Lipid-Calcium-Phosphate ( 177 Lu-LCP) nanoparticles, which provide internal radiation therapy via the beta decay of 177 Lu as well as live animal imaging via 177 Lu's gamma decay 1. One dose of these nanoparticles generated significant and prolonged tumor growth inhibition in two subcutaneous xenograft tumor models with initial tumor volumes of 100-150 mm 3 .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

Satterlee¹,

Rojas²,

Dayton³

et al. 2017

Theranostics

Self Cite

View full text Add to dashboard Cite

Aggressive, desmoplastic tumors are notoriously difficult to treat because of their extensive stroma, high interstitial pressure, and resistant tumor microenvironment. We have developed a combination therapy that can significantly slow the growth of large, stroma-rich tumors by causing massive apoptosis in the tumor center while simultaneously increasing nanoparticle uptake through a treatment-induced increase in the accumulation and retention of nanoparticles in the tumor. The vascular disrupting agent Combretastatin A-4 Phosphate (CA4P) is able to increase the accumulation of radiation-containing nanoparticles for internal radiation therapy, and the retention of these delivered radioisotopes is maintained over several days. We use ultrasound to measure the effect of CA4P in live tumor-bearing mice, and we encapsulate the radio-theranostic isotope 177Lutetium as a therapeutic agent as well as a means to measure nanoparticle accumulation and retention in the tumor. This combination therapy induces prolonged apoptosis in the tumor, decreasing both the fibroblast and total cell density and allowing further tumor growth inhibition using a cisplatin-containing nanoparticle.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

Satterlee¹,

Rojas²,

Dayton³

et al. 2017

Theranostics

Self Cite

View full text Add to dashboard Cite

show abstract

“…A combo treatment of breast and pancreatic cancer was devised, consisting of two separate systems; an anticancer agent called cyclopamine (CPA) combined with liquid-lipid nanoparticles (LLP) and radiolabeled 177 Lu into lipid-calcium-phosphate (LCP) nanoparticles and studied the effect of increased radioisotope on the properties of the nanosystem. The theranostic properties of this radioisotope resulted in tumor remission in H460 and UMUC3/3T3 murine animal models, which could be visualized by SPECT and Cerenkov imaging [105]. 177 Lu-DOTATATE was encapsulated in PLGA nanoparticles coated with PEG, and were assessed regarding their pharmacokinetics and encapsulation efficacy in vitro as well as in rats in vivo.…”

Section: Lutetium-177mentioning

confidence: 99%

Radiolabeled Nanoparticles in Nuclear Oncology

2018

View full text Add to dashboard Cite

A B S T R A C TDuring recent years, a plethora of pioneering radiolabeled nanoparticles have grown to be an integral part of nuclear medicine as theranostic tools. Herein, we focus on the most representative examples of nanoparticles of the past decade, which have been investigated in conjunction with radioisotopes aiming to serve as drug delivery or imaging agents. The present review highlights the key attributes of each nanosystem and the following classification of radiolabeled nanovehicles is based on increasing mass number (A) of radioisotopic elements.

show abstract

“…Recently, 131 I ( t 1/2 = 8 days), often used for the treatment of thyroid cancer, has been integrated with iron oxide nanoparticles and polymeric nanoparticles for targeted therapy of hepatocellular carcinoma in mouse models [133-134]. 177 Lu ( t 1/2 = 6.6 days) has been utilized in lipid-calcium phosphate nanoparticles showing significant growth inhibition in subcutaneous xenograft tumor models [135]. There is also great deal of interest in using a nonradioactive module as a therapeutic partner in the formulation of PET nanoparticles.…”

Section: Therapymentioning

confidence: 99%

Molecular Imaging in Nanotechnology and Theranostics

et al. 2017

View full text Add to dashboard Cite

The “Molecular Imaging in Nanotechnology and Theranostics” (MINT) Interest Group of the World Molecular Imaging Society (WMIS) was founded in 2015 and was officially inaugurated during the 2016 World Molecular Imaging Conference (WMIC). The MINT interest group was created in response to the exponential growth of the fields of Nanotechnology and Theranostics in recent years, and the resulting need to provide a more organized and focused forum on these topics at the WMIS and the WMIC. The overarching goal of MINT is to bring together the many scientists who work on molecular imaging approaches using nanotechnology, and those that work on theranostic agents. MINT therefore represents scientists, labs, and institutes that are very diverse in their scientific backgrounds and areas of expertise, reflecting the wide array of materials and approaches that drive these fields. In this short review, we attempt to provide a condensed overview over some of the key areas covered by MINT. Given the breadth of the fields and the given space constraints, we have limited the coverage to the realm of nano-constructs, although theranostics is certainly not limited to this domain. We will also focus only on the most recent developments of the last 3-5 years, in order to provide the reader with an intuition of what is “in the pipeline” and has potential for clinical translation in the near future.

show abstract

A radio-theranostic nanoparticle with high specific drug loading for cancer therapy and imaging

Cited by 43 publications

References 33 publications

Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

Enhancing Nanoparticle Accumulation and Retention in Desmoplastic Tumors via Vascular Disruption for Internal Radiation Therapy

Radiolabeled Nanoparticles in Nuclear Oncology

Molecular Imaging in Nanotechnology and Theranostics

Contact Info

Product

Resources

About